Moreover, the regulatory mechanism of SGLT-2 inhibitors is insulin-independent; hence, there is generally no risk of hypoglycemia, and it protects β-cells from glucose toxicity [99,100]. The gene discussed is INS; the disease is Hypoglycemia.